CLINICAL TRIALS PROFILE FOR EXENATIDE SYNTHETIC

All Clinical Trials for EXENATIDE SYNTHETIC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	AstraZeneca	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT01046721 ↗	Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms	Completed	University of Nottingham	N/A	2009-09-01	Exenatide is a new drug which lowers blood sugar (glucose) levels for people with type 2 diabetes. It has significant advantages over other treatments such as insulin as it causes weight loss in a group of people that is generally overweight. Data from studies involving exenatide have shown that it also has an effect on blood pressure. The mechanism for the blood pressure lowering effect is not known and has not been investigated previously. Exenatide may have an effect on blood vessels throughout the body and gut to reduce blood pressure. 12 healthy men (18-45yr) will be studied on 2 occasions. Limb blood flow, skin blood flow, gut blood flow, blood pressure, and heart rate will be measured half hourly for 4 hours. Blood samples (3ml) for insulin and glucose determination will be taken via a cannula and 3-way tap at the same time points. A dose of either 5μg exenatide or saline will be injected under the skin of the abdomen and a breakfast will be provided during the study. A urine collection will be made over the duration of the study.
NCT01056549 ↗	Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans	Completed	Eli Lilly and Company	N/A	2010-01-01	Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in vitro studies that have demonstrated an effect
NCT01056549 ↗	Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans	Completed	University Health Network, Toronto	N/A	2010-01-01	Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in vitro studies that have demonstrated an effect

Clinical Trial Conditions for EXENATIDE SYNTHETIC

Condition Name

Condition Name for EXENATIDE SYNTHETIC
Intervention	Trials
Diabetes Mellitus, Type 2	2
Acute Ischemic Stroke	1
Hyperlipidemia	1
Parkinson Disease	1

Condition MeSH

Condition MeSH for EXENATIDE SYNTHETIC
Intervention	Trials
Diabetes Mellitus, Type 2	2
Diabetes Mellitus	2
Ischemia	1
Cerebral Infarction	1

Clinical Trial Locations for EXENATIDE SYNTHETIC

Trials by Country

Trials by Country for EXENATIDE SYNTHETIC
Location	Trials
Australia	5
United Kingdom	2
Taiwan	1
United States	1
Croatia	1

Trials by US State

Trials by US State for EXENATIDE SYNTHETIC
Location	Trials
California	1

Clinical Trial Progress for EXENATIDE SYNTHETIC

Clinical Trial Phase

Clinical Trial Phase for EXENATIDE SYNTHETIC
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for EXENATIDE SYNTHETIC
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	1
Recruiting	1

Clinical Trial Sponsors for EXENATIDE SYNTHETIC

Sponsor Name

Sponsor Name for EXENATIDE SYNTHETIC
Sponsor	Trials
Eli Lilly and Company	2
Karolinska Institutet	1
Center for Neurology, Stockholm	1

Sponsor Type

Sponsor Type for EXENATIDE SYNTHETIC
Sponsor	Trials
Other	9
Industry	3

Last updated: July 26, 2026

Exenatide Synthetic Clinical Trials Update, Market Analysis & Long-Term Revenue Projection (By Formulation and Geography)

Executive summary: Exenatide (synthetic peptide GLP-1 receptor agonist) remains a mature, commercially scaled therapy with clinical focus shifting toward next-generation formulations, comparative effectiveness in type 2 diabetes (T2D), and adherence-enabling regimens. Market exposure is concentrated in subcutaneous GLP-1 usage where exenatide’s differentiators are dosing convenience and long-standing clinical familiarity versus newer agents. Revenue upside is constrained by entrenched GLP-1 class competition and patent/market-entry dynamics across branded products and follow-on reformulations.

Core marketed products (active ingredient: exenatide):

• Byetta (exenatide immediate-release, twice-daily)
• Bydureon / Bydureon BCise (exenatide extended-release, weekly)
• Generic exenatide supply exists in multiple jurisdictions where branded exclusivity lapsed; ongoing competitive pressure is primarily class-level rather than pure exenatide-only.

Clinical trial activity pattern (high level):

• Incremental head-to-head and real-world evidence studies supporting efficacy, tolerability, and persistence against other GLP-1 agents.
• Study designs increasingly target treatment intensification pathways, weight-loss outcomes, cardiovascular risk endpoints where feasible, and adherence endpoints rather than “first efficacy demonstration.”
• Trial activity for synthetic exenatide is less focused on new molecular entities and more on formulation performance, sequence strategies, and comparative outcomes.

Because the prompt does not specify a target branded name, strength, or jurisdiction, a complete, patent-and-trial-scheduled projection requires exact product and geography. Insufficient information is provided to produce an accurate market forecast tied to a specific exenatide synthetic product line and its exclusivity/entry profile.